Corbus to Start Phase 3 Anabasum Trial in Scleroderma Patients by Year’s End
Corbus Pharmaceuticals says a Phase 3 clinical trial of anabasum for diffuse cutaneous scleroderma will start in the fourth quarter of 2017, putting the treatment a step closer toward regulatory approval after a Phase 2 trial that improved patients’ disease. Read more >>